PLK1 and leukemia: Therefore, we assessed the impact of KIFC1 inhibitors [52], as well as inhibitors of the mitotic kinases, aurora kinase A (AURKA) and polo-like kinase 1 (PLK1), on 2 primary Eμ-Ret leukemia samples and the 289 cell line.